🍽️ tridihexethyl chloride,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Gastrointestinal Disorders:

    • Tridihexethyl chloride is classified as an anticholinergic medication and is primarily used to manage gastrointestinal disorders such as peptic ulcers, irritable bowel syndrome (IBS), and gastrointestinal hypermotility.
    • It works by blocking the action of acetylcholine, a neurotransmitter involved in the regulation of smooth muscle contractions in the gastrointestinal tract.
    • By reducing gastrointestinal motility and secretions, tridihexethyl chloride helps alleviate symptoms such as abdominal pain, cramping, diarrhea, and excessive gastric acid secretion.
  2. Antispasmodic Effects:

    • Tridihexethyl chloride has antispasmodic properties, which can help relieve muscle spasms and cramping in the gastrointestinal tract.
    • It may be prescribed to manage symptoms associated with conditions like functional dyspepsia, gastric motility disorders, and gastroesophageal reflux disease (GERD).
  3. Dosage and Administration:

    • Tridihexethyl chloride is typically administered orally in the form of tablets or capsules.
    • The dosage and frequency of administration depend on the patient's age, weight, medical condition, and response to treatment.
    • It is usually taken before meals to maximize its effectiveness in reducing gastrointestinal symptoms.
    • Dosage adjustments may be necessary based on individual patient factors and the severity of symptoms.
  4. Adverse Effects:

    • Common side effects of tridihexethyl chloride may include dry mouth, blurred vision, constipation, urinary retention, drowsiness, dizziness, and confusion.
    • Elderly patients may be more susceptible to adverse effects such as cognitive impairment and delirium.
    • Long-term use of anticholinergic medications like tridihexethyl chloride may increase the risk of cognitive decline and dementia in older adults.
  5. Contraindications and Precautions:

    • Tridihexethyl chloride is contraindicated in patients with a known hypersensitivity to the drug or other anticholinergic agents.
    • It should be used with caution in patients with certain medical conditions such as narrow-angle glaucoma, urinary retention, prostatic hypertrophy, tachycardia, and gastrointestinal obstruction.
    • Patients with a history of cardiac arrhythmias or other cardiovascular disorders should be monitored closely while taking tridihexethyl chloride.
  6. Drug Interactions:

    • Tridihexethyl chloride may interact with other medications, including anticholinergic drugs, central nervous system depressants, antihistamines, and certain antidepressants.
    • Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.
;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of tridihexethyl chloride,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by tridihexethyl chloride,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Lacticaseibacillus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Bacteroides genus Decreases 👪 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Agathobacter rectalis species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Ruminococcus bromii species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of tridihexethyl chloride,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
ADHD 0.4 0.4
Allergic Rhinitis (Hay Fever) 1.4 1.4
Allergies 0.9 0.8 0.13
Allergy to milk products 0.8 0.3 1.67
Alzheimer's disease 1 1.8 -0.8
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0.8 -0.33
Ankylosing spondylitis 1.3 1.2 0.08
Anorexia Nervosa 0.5 -0.5
Antiphospholipid syndrome (APS) 0.6 0.1 5
Asthma 0.1 -0.1
Atherosclerosis 0.2 0.2
Atrial fibrillation 0.5 0.9 -0.8
Autism 2.2 1.9 0.16
benign prostatic hyperplasia 0.3 0.3
Biofilm 1.6 1.6
Bipolar Disorder 0.7 0.2 2.5
Brain Trauma 0.1 -0.1
Cancer (General) 0.6 -0.6
Carcinoma 0.7 0.3 1.33
Celiac Disease 0.7 0.4 0.75
Cerebral Palsy 0.3 -0.3
Chronic Fatigue Syndrome 2.6 0.8 2.25
Chronic Kidney Disease 1.6 0.5 2.2
Chronic Lyme 0.1 -0.1
Chronic Urticaria (Hives) 0.9 0.8 0.13
Coagulation / Micro clot triggering bacteria 0.9 0.2 3.5
Colorectal Cancer 1.5 0.3 4
Constipation 0.4 0.4
Coronary artery disease 1.4 1.4
COVID-19 1.2 1.8 -0.5
Crohn's Disease 2.6 1.1 1.36
cystic fibrosis 0.9 0.1 8
deep vein thrombosis 0.9 0.2 3.5
Depression 1.6 1.9 -0.19
Eczema 1.3 0.3 3.33
Endometriosis 1 0.2 4
Epilepsy 0.7 0.1 6
Fibromyalgia 0.5 -0.5
Functional constipation / chronic idiopathic constipation 1.5 1.1 0.36
gallstone disease (gsd) 0.5 0.5
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.3 0.3
Generalized anxiety disorder 1.9 0.1 18
Graves' disease 0.1 0.1
Halitosis 0.1 0.1
Hashimoto's thyroiditis 0.3 0.2 0.5
Hidradenitis Suppurativa 0.1 0.1
High Histamine/low DAO 0.6 0.2 2
hyperglycemia 0.3 0.1 2
hypersomnia 0.1 -0.1
hypertension (High Blood Pressure 0.5 0.5 0
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 1.4 -1.4
Inflammatory Bowel Disease 2.3 2.1 0.1
Insomnia 0.1 0.1 0
Intelligence 0 0.4 0
Intracranial aneurysms 0.3 0.3
Irritable Bowel Syndrome 1.1 0.1 10
Liver Cirrhosis 0.7 0.4 0.75
Long COVID 1.6 0.9 0.78
Lung Cancer 0.3 0.2 0.5
Mast Cell Issues / mastitis 0.3 0.2 0.5
ME/CFS with IBS 0.1 -0.1
ME/CFS without IBS 1.1 0.1 10
Metabolic Syndrome 2.6 0.7 2.71
Mood Disorders 1.9 1.9 0
Multiple Sclerosis 0.3 1.5 -4
Multiple system atrophy (MSA) 0.2 -0.2
neuropathic pain 0.1 -0.1
Neuropathy (all types) 0.3 -0.3
neuropsychiatric disorders (PANDAS, PANS) 0.6 0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.7 0.8 -0.14
Obesity 1.9 0.9 1.11
obsessive-compulsive disorder 1.7 2 -0.18
Osteoarthritis 1.4 0.2 6
Osteoporosis 0.5 0.1 4
Parkinson's Disease 0.7 1.1 -0.57
Polycystic ovary syndrome 0.5 0.3 0.67
primary biliary cholangitis 0 0
Psoriasis 1.1 0.5 1.2
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.1 0.4 4.25
Rosacea 0.4 0.4
Schizophrenia 0.4 0.2 1
scoliosis 0.3 -0.3
Sjögren syndrome 0.7 0.4 0.75
Sleep Apnea 0.2 0.1 1
Slow gastric motility / Gastroparesis 0.8 0.8
Small Intestinal Bacterial Overgrowth (SIBO) 0.6 0.6
Stress / posttraumatic stress disorder 0.7 0.1 6
Systemic Lupus Erythematosus 1.8 0.2 8
Tic Disorder 0.2 0.4 -1
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 1 1
Type 2 Diabetes 2.6 1.2 1.17
Ulcerative colitis 1.3 0.7 0.86
Unhealthy Ageing 1.8 0.5 2.6

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]